Skip to content

Canceled by the investigator Study on the effect of combined transcranial electromagnetic stimulation on behavioral and psychological symptoms of AD patients and its brain network mechanism

Study on the effect of combined transcranial electromagnetic stimulation on behavioral and psychological symptoms of AD patients and its brain network mechanism

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100044649
Enrollment
Unknown
Registered
2021-03-25
Start date
2021-04-01
Completion date
Unknown
Last updated
2021-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

behavioral and psychological symptoms of dementia

Interventions

Combined stimulation group:Subjects received rTMS true stimulation combined with tDCS true stimulation
Single rTMS stimulation group:Subjects receive rTMS true stimulus and tDCS false stimulus
Single tDCS stimulation group:Subjects receive rTMS false stimulus and tDCS true stimulus
Control group:The electromagnetic stimuli received by the subjects are all pseudo stimuli

Sponsors

Beijing Geriatric Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Right-handed; 2. Gender is not limited, age 60-90 years; 3. AD diagnosis meets NINCDS-ADRDA diagnosis is likely to be AD, and at the same time meets the clinical dementia severity score (CDR) >= 2 points and the disease course is within 10 years; 4. There are mental symptoms (such as hallucinations, delusions, etc.), behavioral symptoms (such as nighttime behavioral stereotypes, aggression, disinhibition, etc.), emotional symptoms (such as depression/unhappy mood, anxiety, euphoria, over-excitement/high mood, etc.) And other mental and behavioral symptoms; 5. Educational level is junior high school and above; 6. Can cooperate to complete neuropsychological assessment and head MRI and TMS-EEG examinations, without examination contraindications; 7. If you are taking AD drugs, you need to take the drugs. >= 4 weeks, and no drug dosage adjustment during the treatment period; 8. Subjects or immediate family members agree to participate in this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Those with functional failure and critical illness of important organs (heart, lung, liver, kidney, etc.); 2. Those with metal implants such as cardiac pacemakers, coronary stents and aneurysm clips, and artificial implants. Into the cochlea and other ferromagnetic materials. 3. People with severe visual and hearing impairment; 4. People who are undergoing other clinical trials; 5. People who have history of infectious diseases, brain trauma and surgery; 6. People who have alcoholism and drug addiction.

Design outcomes

Primary

MeasureTime frame
Neuropsychiatric Inventory, NPI;

Secondary

MeasureTime frame
Geriatric Depression Scale;Pittsburgh Sleep Quality Index, PSQI;Mini-mental State Examination, MMSE;Montreal Cognitive Assessment, MoCA;Alzheimer' s Disease Assessment Scale-cognitive subscale, ADAS-Cog;Barthel Index, BI;fMRI, TMS-EEG?resting state EEG;

Countries

China

Contacts

Public ContactYueqing Hu

Beijing Geriatric Hospital

hyqing1987@163.com+86 10-83183801

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026